1. Home
  2. SLGL vs WEA Comparison

SLGL vs WEA Comparison

Compare SLGL & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

N/A

Current Price

$42.02

Market Cap

117.8M

Sector

Health Care

ML Signal

N/A

Logo Western Asset Bond Fund Share of Beneficial Interest

WEA

Western Asset Bond Fund Share of Beneficial Interest

HOLD

Current Price

$10.97

Market Cap

130.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLGL
WEA
Founded
1997
2002
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
117.8M
130.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
SLGL
WEA
Price
$42.02
$10.97
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$50.00
N/A
AVG Volume (30 Days)
15.1K
46.1K
Earning Date
11-20-2025
01-01-0001
Dividend Yield
N/A
7.87%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,970,000.00
N/A
Revenue This Year
$121.82
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
62.04
N/A
52 Week Low
$4.02
$9.60
52 Week High
$52.26
$11.29

Technical Indicators

Market Signals
Indicator
SLGL
WEA
Relative Strength Index (RSI) 55.90 44.08
Support Level $39.26 $10.90
Resistance Level $44.04 $11.03
Average True Range (ATR) 3.07 0.10
MACD -0.03 -0.01
Stochastic Oscillator 66.20 23.33

Price Performance

Historical Comparison
SLGL
WEA

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

About WEA Western Asset Bond Fund Share of Beneficial Interest

Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.

Share on Social Networks: